Neuropore Therapies, Inc. is a San Diego, California based biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for the treatment Parkinson’s disease and other neurodegenerative disorders. The approaches applied by Neuropore Therapies target the core pathological processes underlying these disorders including the intracellular accumulation of neurotoxic misfolded proteins and neuroinflammation.
The first clinical candidate to emerge from our discovery efforts is NPT200-11. This is an orally bioavailable small molecule that uniquely targets the earliest steps in the processes leading to the formation of alpha-synuclein (ASYN) toxic oligomeric protein aggregates involved in Parkinson’s disease (PD) and other related disorders. Concomitant with our successful execution of a Phase 1 clinical trial, this candidate was out-licensed to UCB Pharma for a total potential value of $480 million plus up to double digit royalties on net sales. Beyond the continuing development of NPT200-11, Neuropore Therapies is advancing a number of additional preclinical stage compounds, with complementary mechanisms of action (i.e. enhancing the clearance of proteins that have already formed toxic aggregates and/or mitigating their toxic neuroinflammatory actions).